Publications

Deucravacitinib onset of action and maintenance of response in Phase 3 plaque psoriasis trials

J Dermatolog Treat 2024;35:2371045 doi: 10.1080/09546634.2024.2371045

Korman NJ,

Warren RB,

Bagel J,

Armstrong AW,

Gooderham M,

Strober B,

Thaçi D,

Morita A,

Imafuku S,

Foley P,

Sofen H,

Zheng M,

Hippeli L,

Kisa RM,

Banerjee S,

Blauvelt A

The analysis of the POETYK PSO-1 and POETYK PSO-2 clinical trials showed that deucravacitinib 6mg QD displayed efficacy as early as 1 week, and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.

Keywords:

• Deucravacitinib,
• Efficacy,
• Phase 3

The outcomes of children born to mothers with autoimmune rheumatic diseases

Lancet Rheumatol 2024:S2665-9913(24)00096-1 doi: 10.1016/S2665-9913(24)00096-1 Epub ahead of print

Andreoli L,

Andersen J,

Avcin T,

Chambers CD,

Fazzi EM,

Marlow N,

Wulffraat NM,

Tincani A

This Series paper by Andreoli, et al. provides a comprehensive overview of the literature for pregnancy outcomes for mothers with autoimmune rheumatic disease, and provides guidance on discussing these topics with patients. They also provide a list of frequently asked questions related to pregnancy and children by women with autoimmune rheumatic diseases.

Keywords:

• IL-6,
• Outcomes,
• Pregnancy / Fertility,
• Recommendations,
• TNF

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis

Am Acad Dermatol 2023. doi: 10.1016/j.jaad.2023.11.060

Blauvelt A,

Rich P,

Sofen H,

Strober B,

Merola JF,

Lebwohl M,

Morita A,

Szepietowski JC,

Lambert J,

Hippeli L,

Colston E,

Balagula E,

Banerjee S,

Thaçi D

This pooled analysis of the Phase 3 PSO-1 and PSO-2 trials shows that deucravacitinib has greater efficacy in treating scalp PsO than placebo and apremilast. At week 16, response rates were greater with deucravacitinib versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 and Psoriasis Scalp Severity Index. Efficacy was maintained through 52 weeks in patients who received continuous deucravacitinib treatment.

Keywords:

• Apremilast,
• Deucravacitinib,
• Efficacy,
• Outcomes,
• Phase 3,
• Remission,
• Safety

Étude rétrospective de l'efficacité des inhibiteurs de JAK ou de l'abatacept sur la polyarthrite rhumatoïde et la pneumopathie interstitielle

Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w

Tardella M,

 Di Carlo M,

 Carotti M,

 Ceccarelli L,

 Giovagnoni A,

 Salaffi F.

This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.

Keywords:

• JAK,
• Safety,
• Lung / ILD,
• Review

Étude Comparative d'Innocuité Post-Approbation du Tofacitinib et des Antirhumatismaux Biologiques : Résultats à 5 ans à partir d'un Registre de Polyarthrite Rhumatoïde Basé aux États-Unis

ACR Open Rheumatol. 2021 Feb 11.

Kremer JM,

Bingham CO 3rd,

Cappelli LC,

Greenberg JD,

Madsen AM,

Geier J,

Rivas JL,

Onofrei AM,

Barr CJ,

Pappas DA,

Litman HJ,

Dandreo KJ,

Shapiro AB,

Connell CA,

Kavanaugh A

Analysis from the US Corrona RA registry has provided the longest-term real-world safety data for a JAK inhibitor to date. The analysis showed that the cohorts had similar adverse events, except for higher herpes zoster rates for tofacitinib initiators vs bDMARDs.Kremer JM, et al. analysed adult patients with RA newly initiating tofacitinib, or a bDMARD, to compare incidence rates of MACE, SIEs, HZ, malignancies and death. VTE data were also collected prospectively and assessed descriptively thr...

Keywords:

• JAK,
• Tildrakizumab,
• Real-World

Baricitinib in Patients with Refractory Rheumatoid Arthritis

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247

Genovese et al.

For patients who have an inadequate response or unacceptable side effects associated with biologic DMARDs, the options for treatment beyond conventional DMARDs are limited. This phase 3 trial of the JAK 1/2 inhibitor, baricitinib, studied its efficacy in bDMARD-IR patients. 527 patients were randomized to either baricitinib 2mg, 4mg or placebo for up to 24 weeks. At week 12 the primary endpoints were tested hierarchically to control type 1 error; these endpoints were ACR20, HAQ-DI score, DAS28-C...

Keywords:

• JAK,
• Baricitinib,
• Review

A meta-analysis of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis

Clinical Rheumatology 2013 doi 10.1007/s10067-013-2340-1

Li L,

Li G,

Yu C,

Li Y

The role of p38-MAPK inhibitors in treating RA is the subject of some debate. Li et al. therefore performed the first meta-analysis of the current data to evaluate the efficacy and safety of these compounds. The authors identified 3 papers, covering 4 RCTs, for analysis and the results showed that p38-MAPK inhibition achieves a better level of ACR20 improvement vs. placebo, but showed no meaningful difference in ACR50, DAS28 or CRP levels past week 12. Due to the inadequate number and quality of...

Keywords:

• p38 MAPK,
• Review